<DOC>
	<DOCNO>NCT00998634</DOCNO>
	<brief_summary>The purpose study determine safety tolerability treatment lithium Spinocerebellar Ataxia 2 . Moreover , clinical symptom , neuronal loss , quality life depressive symptom , consider investigate effect lithium therapy .</brief_summary>
	<brief_title>Safety Tolerability Lithium Spinocerebellar Ataxia 2 ( SCA2 )</brief_title>
	<detailed_description>Patients progressively enrol study undergo screen visit test inclusion/exclusion criterion . Patients randomize receive either Lithium carbonate placebo . Patients visit study center 2 , 4 , 8 , 12 , 24 , 36 48 week , endpoint laboratory assessment .</detailed_description>
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Cerebellar Ataxia</mesh_term>
	<mesh_term>Spinocerebellar Ataxias</mesh_term>
	<mesh_term>Spinocerebellar Degenerations</mesh_term>
	<mesh_term>Lithium Carbonate</mesh_term>
	<criteria>Molecular diagnosis SCA2 ( ≥34 CAG ataxin2 gene ) Age ≥18 , &lt; 80 SARA score ≥8 SARA score &gt; 32 Heart failure Liver disease Kidney failure Thyroid disease Sick sinus syndrome and/or significant ECG alteration Hyposodemia Treatment diuretic Treatment haloperidol and/or antipsychotic Treatment NSAIDs corticosteroid Treatment ACE inhibitor Treatment aminophylline Treatment mannitol Pregnancy and/or breastfeed Acute disease might interfere trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>SCA2</keyword>
	<keyword>Lithium</keyword>
</DOC>